 HOUSTON, April 05, 2021 GLOBE NEWSWIRE -- Bio-Path Holdings, Inc., NASDAQ:BPTH, a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the successful completion of the safety run-in of the Stage 2 of the Phase 2 clinical study of prexigebersen BP1001, a liposomal Grb2 antisense, for the treatment of acute myeloid leukemia AML, in combination with frontline therapies, decitabine and venetoclax, in acute myeloid leukemia AML patients. The safety run-in of Stage 2 of the Phase 2 clinical trial was comprised of six evaluable patients who were treated with the triple combination of prexigebersen, decitabine and venetoclax. 